Investing.com - Century Therapeutics (NASDAQ: IPSC) reported first quarter EPS of $-0.450, $0.06 better than the analyst estimate of $-0.514. Revenue for the quarter came in at $855K versus the consensus estimate of $212.5K.
Century Therapeutics's stock price closed at $3.07. It is down -28.600% in the last 3 months and down -9.330% in the last 12 months.
Century Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Century Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Century Therapeutics's Financial Health score is "fair performance".
Check out Century Therapeutics's recent earnings performance, and Century Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar